Insights
Professional
Practice
Industry
Region
Trending Topics
Location
Type
Sort by:
Firm News 7 results
Firm News | 8 min read | 08.15.24
Washington – August 15, 2024: The 2025 edition of The Best Lawyers in America® has recognized 42 Crowell & Moring lawyers as "Best Lawyers" and 29 lawyers as “Ones to Watch.”
Firm News | 2 min read | 05.30.24
Crowell & Moring Honors Recipients of 25th Annual George Bailey Public Service Awards
Washington, D.C. – May 30, 2024: Crowell & Moring hosted its 25thannual George Bailey Public Service Awards ceremony. Named after the hero of the classic movie, “It’s a Wonderful Life,” these awards recognize the firm’s lawyers and staff who have made a substantial impact on the lives of others through their pro bono work.
Firm News | 8 min read | 08.17.23
Washington – August 17, 2023: The 2024 edition of The Best Lawyers in America® has recognized 47 firm lawyers as "Best Lawyers" and 41 lawyers as “Ones to Watch.”
Client Alerts 9 results
Client Alert | 4 min read | 01.31.25
On January 24, 2025, the United States Supreme Court agreed to hear a case that could resolve whether putative Rule 23(b)(3) classes may be certified in the federal courts when some of the class members are uninjured. Or, as the Supreme Court put the certified question in the case, Laboratory Corporation of America Holdings, dba Labcorp, v. Luke Davis, et al., No. 22-55873:
Client Alert | 3 min read | 12.24.24
Only Drugs Allowed: Federal Circuit Affirms Order To Delist Device Patents From the Orange Book
On December 20, 2024, the Federal Circuit affirmed a district court’s holding that five device patents had been improperly listed in the Orange Book by Teva Pharmaceuticals, Inc. as claiming a drug, and ordering that they be delisted.
Client Alert | 2 min read | 06.27.24
As reported in earlier Client Alerts, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In response, some manufacturers withdrew their patents, and others agreed to cap certain out-of-pocket costs for their drugs, resulting in a “victory lap” of media activity from the FTC in April.
Press Coverage 1 result
Press Coverage | 08.15.22
A Lawsuit Over Products Marketed as “100% Recyclable” Has Lessons for Fashion
The Fashion LawPublications 3 results
Publication | 05.14.24
2024 Lexology Advertising and Marketing USA
Crowell attorneys prepared Lexology’s Advertising and Marketing USA reference guide enabling side-by-side comparison of a variety of countries’ advertising and marketing standards, including the legal and regulatory framework; private enforcement (litigation and administrative procedures); misleading advertising; prohibited and controlled advertising; social media advertising; and recent trends.
Publication | 04.10.23